UroAlert - GU Oncology Weekly

October 17, 2024

Videos

Peer-to-Peer Clinical Conversations

Hypofractionated Radiotherapy Efficacy for Post-Prostatectomy Patients - Asunción Hervás

Asunción Hervás

Asunción Hervás disccusses the HYPORT-ES trial, which examines hypofractionated postoperative radiotherapy in prostate cancer.

NIAGARA Trial: Chemo Plus Durvalumab Improves Survival in Muscle-Invasive Bladder Cancer - Thomas Powles

Thomas Powles

Shilpa Gupta interviews Thomas Powles about the NIAGARA study, which examines perioperative chemoimmunotherapy in muscle-invasive bladder cancer.

Beyond the Abstracts

Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer - Beyond the Abstract

Integrative Multi-Region Molecular Profiling of Primary Prostate Cancer in Men with Synchronous Lymph Node Metastasis - Beyond the Abstract

Conference Coverage

ASTRO 2024: A Randomized Comparison of Low Dose Rate or High Dose Rate Brachytherapy Combined with External Beam Radiation for Unfavorable Intermediate or High-risk Prostate Cancer: Efficacy Results at Median 6 Years

ASTRO 2024: SBRT for Unfavorable Intermediate-Risk Prostate Cancer

ASTRO 2024: Role of ADT and Genomic Risk Stratification for Patients with Unfavorable Intermediate-Risk Prostate Cancer

ASTRO 2024: Strategies and Evidence for SABR in RCC

ASTRO 2024: Integrating Novel Therapeutics with Trimodal Therapy (TMT)

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Development of a new radical cystectomy surveillance protocol and nurse-led cystectomy follow-up clinic in Australia.

The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond.

Effects of Intraoperative Opioid Use and a Combined Anesthesia Protocol in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder-A Single-Center Experience.

Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec.

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: Lessons learned about management and patient enrollment in a large, pragmatic, patient-centered trial.

Tumor location at trans-urethral resection is predictive of ipsilateral pelvic lymph-nodal metastases in patients undergoing radical cystectomy for bladder cancer.

Transition in Quality Of Life Among Older Patients With Bladder Cancer and Its Association With Treatment: A Clustering Approach

VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol.

Oncologic outcomes of pelvic organ-preserving radical cystectomy vs. Standard radical cystectomy: A systematic review and meta-analysis.

Analysis of the Application of the Micrometric Substaging System to Predict Recurrence and Progression in a Cohort of Patients with pT1 High-Grade Non-Muscle Invasive Bladder Cancer.

Strategies to Improve Clinical Outcomes and Patient Experience Undergoing Transurethral Resection of Bladder Tumor.

Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles.

Novel intravesical therapies and delivery systems for the management of bladder cancer.

Predicting response to intravesical BCG in high-risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort.

Penile & Urethral Cancers

Serum cyfra21-1 is a new prognostic biomarker of penile squamous cell carcinoma.

Molecular Characterization of Metastatic Penile Squamous Cell Carcinoma in Developing Countries and Its Impact on Clinical Outcomes: LACOG 2018 Translational Study - Beyond the Abstract

Renal Cancer

Stereotactic Body Radiotherapy (SBRT) for the Treatment of Primary Localized Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Cost-effectiveness of pembrolizumab as an adjuvant treatment of renal cell carcinoma post-nephrectomy in Switzerland.

Stereotactic Body Radiotherapy for Renal Cell Carcinoma-A Review of Use in the Primary, Cytoreductive and Oligometastatic Settings.

Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF-2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma.

Dense Collagen I as a Biomimetic Material to Track Matrix Remodelling in Renal Carcinomas.

Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the novel NAMPT Inhibitor OT-82.

Ultra-processed food consumption and renal cell carcinoma incidence and mortality: results from a large prospective cohort.

Predicting post-surgical complications using renal scoring systems.

The Influence of Pre-ablation Embolization Particle Size on the Size of the Microwave Ablation Zone in a Porcine Orthotopic Renal Tumor Model.

Sample Site Impacts RNA Biomarkers for Renal Cell Carcinoma.

Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population.

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1) - Beyond the Abstract

Diagnostic Accuracy and Safety of Renal Tumour Biopsy in Patients with Small Renal Masses and Its Impact on Treatment Decisions - Beyond the Abstract

Prostate Cancer

Copper-67 SAR-bisPSMA Updates

Machine learning and explainable artificial intelligence to predict pathologic stage in men with localized prostate cancer.

External Validation of a Previously Developed Deep Learning-based Prostate Lesion Detection Algorithm on Paired External and In-House Biparametric MRI Scans.

Accuracy of the LaserSAFE technique for detecting positive surgical margins during robot-assisted radical prostatectomy: blind assessment and inter-rater agreement analysis.

General Obesity and Prostate Cancer in Relation to Abdominal Obesity and Ethnic Groups: A US Population-Based Cross-Sectional Study.

Investigating the pattern of prostate specific antigen screening among E-cigarette smokers within the behavioral risk factor surveillance system.

Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial.

Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies.

Identification of a 5-gene signature panel for the prediction of prostate cancer progression.

Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval.

Association between smoking and prostate cancer survivors' long-term quality of life and function: an analysis of the CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation) study.

Positive Guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III Trial in Patients with Recurrence of Prostate Cancer

Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy.

The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617.

Prospective, Randomized Controlled Pivotal Trial of Biodegradable Balloon Rectal Spacer for Prostate Radiation Therapy

Five-Year Prostate-Specific Membrane Antigen Positron Emission Tomography-Based Outcomes of Spot-Scanning Proton Radiation Therapy for Localized Prostate Cancer: A Single Institution Experience

Aiming High: Prostate-specific Membrane Antigen Expression in Treatment-naïve Prostate Cancer.

The Immune Microenvironment in Prostate Cancer: A Comprehensive Review.

PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients

Systemic immune-inflammation index is associated with high risk for prostate cancer among the U.S. elderly: Evidence from NHANES 2001-2010.

Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial

Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer.

Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial.

"I Just Had to Do What I Had to Do": Characterizing Direct and Indirect Prostate Cancer Treatment Costs for Black Survivors and Their Caregivers.

Perturbations in the blood metabolome up to a decade before prostate cancer diagnosis in 4387 matched case-control sets from the European Prospective Investigation into Cancer and Nutrition.

Methylation-based immune deconvolution in prostate cancer patients before and after radical prostatectomy.

Detection of Germline Variants in Patients with Localized and Metastatic Prostate Cancer through Guideline-Based Testing.

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).

Loss of PI5P4Kα slows the progression of a Pten mutant basal cell model of prostate cancer.

Post-Treatment surveillance intensity and overall survival in prostate cancer survivors (AFT-30).

Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer.

Prostate cancer and solid organ transplantation: patient management and outcomes.

Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx

Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel

Cone-Beam Computed Tomography (CBCT)-Based Online Adaptive Radiation Therapy (oART) for a Prostate Cancer Patient With Inflammatory Bowel Disease and Bilateral Total Hip Arthroplasty: A Case Report.

Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?

Targeted Biopsy is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer.

A Phase I Trial of Image-Guided, Risk-Volume-Adapted Post-Prostatectomy Radiotherapy.

Radiotherapy and theranostics: a Lancet Oncology Commission.

Nivolumab in patients with metastatic castration-resistant prostate cancer with and without DNA repair defects.

Testing home-based exercise strategies in underserved minority cancer patients undergoing chemotherapy (THRIVE) trial: a study protocol.

Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer.

Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression.

Peripheral blood interferon responses to toll-like receptor 1/2 signaling associate with longer survival in men with metastatic prostate cancer treated with Sipleucel-T.

Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics.

Survival of Men with Metastatic Hormone-Sensitive Prostate Cancer and Adrenal-Permissive HSD3B1 Inheritance - Beyond the Abstract

Prediction of Undetectable Circulating Tumor DNA by Comprehensive Genomic Profiling Assay in Metastatic Prostate Cancer: The SCRUM-Japan MONSTAR SCREEN Project - Beyond the Abstract

Upper Tract Tumors

Role of neoadjuvant chemotherapy in patients with locally advanced and clinically positive nodes Upper Tract Urothelial Carcinoma treated with Nephroureterectomy: real-world data from the ROBUUST 2.0 Registry.

Testicular Cancer

High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed or refractory testicular cancer: a systematic review and meta-analysis.

Short and long-term outcomes of arterial and caval replacement during postchemotherapy retroperitoneal lymph node dissection in metastatic testicular cancer.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC